Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study on combination of capecitabine and oxaliplatin in patients with relapsed or refractory gastric cancer

Next Previous
Search
Trial Profile

Phase II study on combination of capecitabine and oxaliplatin in patients with relapsed or refractory gastric cancer

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use

Most Recent Events

  • 29 Jan 2010 Planned end date changed from 1 Dec 2009 to 1 Feb 2010 as reported by ClinicalTrials.gov record.
  • 29 Jan 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
  • 24 Dec 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top